(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 43.43% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.75%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.49%.
Eton Pharmaceuticals's revenue in 2026 is $86,934,000.On average, 6 Wall Street analysts forecast ETON's revenue for 2026 to be $3,390,352,150, with the lowest ETON revenue forecast at $3,224,354,460, and the highest ETON revenue forecast at $3,531,970,641. On average, 6 Wall Street analysts forecast ETON's revenue for 2027 to be $5,222,626,976, with the lowest ETON revenue forecast at $4,764,078,903, and the highest ETON revenue forecast at $5,479,293,371.
In 2028, ETON is forecast to generate $7,026,139,827 in revenue, with the lowest revenue forecast at $6,353,383,515 and the highest revenue forecast at $7,921,869,934.